The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more

RAG rating
n/a
Document type
Clinical pathways
Place
Hertfordshire and West Essex ICB
Output type
Clinical Pathways
Pathway
Treatment for Hyperhidrosis in Primary Care

Hyperhidrosis Management

Primary/Focal Hyperhidrosis:

  • Conduct baseline HDSS score
  • first line management commercial antiperspirant with 20% aluminium chloride hexahydrate e.g. Driclor® and Anhydrol Forte® which may be purchased (if skin irritation occurs and other conservative measures fail consider adding 1% hydrocortisone cream - see NICE guidance as above). Advise to purchase over the counter.
  • If treatment unsuccessful** after one month recommend further self-management with iontophoresis (patient to purchase) if axillary or palmar/plantar hyperhidrosis, or consider oral anticholinergic* (off label).
  • If self-management (including oral anticholinergic if tried) not successful** after 3-6 months, manage according to severity
    • If HDSS score 1-3 stop treatment
    • If HDSS score 4 despite all self-management treatments as above, refer to skin health triage

Secondary Hyperhidrosis: address cause if known (e.g. hyperthyroidism, menopause, medication, amphetamines), if unknown cause refer to secondary care for investigation as appropriate.

NOTES

*First-line Oxybutynin 2.5mg IR: start with 2.5mg OD & gradually titrate according to response. 

Alternative anticholinergics can be tried but lack evidence (off-label).

Propantheline bromide is licensed for hyperhidrosis but less effective.  Oral glycopyrronium bromide is unlicensed in the UK & costs are prohibitive: evidence base is similar as for oxybutynin.

**Criteria for successful treatment of hyperhidrosis: reduction in HDSS score.  Treatment failure can be defined as no change in HDSS score after 1 month of therapy or lack of tolerability for the treatment.

For further information, see Priorities Forum statement The Management of Hyperhidrosis https://www.nhs.uk/conditions/excessive-sweating-hyperhidrosis/

Back